Inrebic (Fedratinib)

Fedratinib works by selectively inhibiting the Janus kinase 2 (JAK2) enzyme, a key component of the JAK‑STAT signaling pathway that drives the growth of malignant blood cells. Blocking JAK2 reduces downstream signaling, limiting the proliferation and survival of the abnormal hematopoietic clones responsible for myelofibrosis.

The dose of Inrebic is determined by the prescribing healthcare professional based on the patient’s clinical condition, disease severity, and laboratory parameters. The prescriber will select the appropriate strength and dosing schedule according to the product labeling and individual patient needs.

Safety data for Inrebic in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women of childbearing potential should discuss contraception and risk with their healthcare provider before starting therapy.

To order Inrebic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

The primary alternative to Inrebic is ruxolitinib, a JAK1/2 inhibitor. While both target the JAK‑STAT pathway, fedratinib is more selective for JAK2 and may be preferred in patients who have progressed after ruxolitinib or who have specific JAK2‑driven disease characteristics. Efficacy and safety profiles differ, so treatment choice depends on individual patient factors.

Inrebic tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect them from moisture. Keep the container tightly closed and out of direct sunlight. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Inrebic is taken orally as a tablet with a full glass of water. It is usually taken once daily, but the exact schedule is set by the prescribing clinician. Patients should follow any specific instructions regarding food intake or timing relative to other medications as indicated in the prescribing information.

The most serious risks include Wernicke encephalopathy, which can result from thiamine deficiency, severe infections due to immunosuppression, and hepatotoxicity manifested by elevated liver enzymes. Patients should be monitored closely for neurological symptoms, signs of infection, and liver function abnormalities throughout treatment.

Inrebic should be avoided in patients with known hypersensitivity to fedratinib or any tablet excipients, in those with active severe infections, and in individuals with uncontrolled liver disease. Caution is also advised for patients with a history of thiamine deficiency or those taking strong CYP3A4 inhibitors without appropriate dose adjustments.